Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
AcelRx (ACRX) Could Have Positive AdCom Vote - Cantor Fitzgerald
-
Freddie Mac Prices $1.1 Billion Multifamily K-Deal, K-081
-
ChaSerg Technology Acquisition Corp. (CTAC) Prices 20M Units IPO at $10/Unit
-
ChaSerg Technology Acquisition Corp. Announces Pricing of $200 Million Initial Public Offering
-
ChaSerg Technology Acquisition Corp. Announces Pricing of $200 Million Initial Public Offering
-
Kevin Parks Named STA’s 2018 Dictum Meum Pactum Award Recipient
-
Amarin Corporation (AMRN) PT Raised to Street High $35 at Cantor Fitzgerald
-
Arrowhead Research (ARWR) PT Raised to $24 at Cantor Fitzgerald
-
SeaSpine Holdings (SPNE) PT Raised to $22 at Cantor Fitzgerald
-
Kala Pharmaceuticals (KALA) Prices 7.5M Common Stock Offering at $8.25 per Share
-
Kala Pharmaceuticals Announces Pricing of Public Offering of 7,500,000 Shares of Common Stock
-
Rockrose Energy PLC (RRE:LN) PT Raised to GBP873 at Cantor Fitzgerald
-
CytoSorbents to Present at the Cantor Fitzgerald Global Healthcare Conference
-
Kala Pharmaceuticals (KALA) Commences 7.5M Share Public Offering of Common Stock
-
Kala Pharmaceuticals Announces Proposed Public Offering of Common Stock
-
Ra Medical Systems Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
-
Allscripts to present at the 2018 Cantor Fitzgerald Global Healthcare Conference
-
Foamix (FOMX) Announces Additional Positive Topline Results from Third Phase 3 Trial Evaluating FMX101
-
Foamix Announces Additional Positive Topline Results from Third Phase 3 Trial (Study FX2017-22) Evaluating FMX101 Topical Minocycline Foam for Moderate-to-Severe Acne
-
Insmed to Present at Two October Conferences
-
Cantor Fitzgerald Starts Alnylam Pharmaceuticals (ALNY) at Overweight
-
Cantor Fitzgerald Starts MyoKardia (MYOK) at Overweight
-
Cantor Fitzgerald Starts Celgene (CELG) at Overweight
-
Cantor Fitzgerald Starts BioMarin Pharmaceutical Inc. (BMRN) at Overweight
-
Cantor Fitzgerald Starts Regeneron Pharma (REGN) at Neutral
-
Cantor Fitzgerald Starts Puma Biotechnology (PBYI) at Overweight
-
Cantor Fitzgerald Starts Incyte (INCY) at Neutral
-
Cantor Fitzgerald Starts Vertex (VRTX) at Overweight
-
Cantor Fitzgerald Starts Amgen (AMGN) at Neutral
-
Cantor Fitzgerald Transfers Coverage on Intercept Pharmaceuticals (ICPT), Upgrades to Overweight
-
Cantor Fitzgerald Starts PTC Therapeutics (PTCT) at Overweight
-
Cantor Fitzgerald Starts Gilead Sciences (GILD) at Overweight
-
Cantor Fitzgerald Transfers Coverage on Biogen (BIIB), Upgrades to Overweight
-
Cantor Fitzgerald Starts Tesaro (TSRO) at Overweight
-
Cantor Fitzgerald Starts Sarepta Therapeutics (SRPT) at Overweight
-
Opiant Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Opiant Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Apellis Pharmaceuticals to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference
-
Apellis Pharmaceuticals to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference
-
Abeona Announces Participation at Upcoming Conferences
-
Abeona Announces Participation at Upcoming Conferences
-
Agenus to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference in New York, NY
-
TG Therapeutics, Inc. to Present at Upcoming Investor Conferences
-
UPDATE: Opiant Pharma (OPNT) PT Raised to $42 at Cantor Fitzgerald
-
Teladoc (TDOC) PT Raised to $83 at Cantor Fitzgerald Following Investor Day
-
Aldeyra Therapeutics (ALDX) Prices 5.25M Share Common Offering at $13.75/Sh
-
Aldeyra Therapeutics, Inc. Announces Public Offering of Common Stock
-
Veru to Present at Upcoming Healthcare Investor Conferences in New York
-
XOMA to Present at the Cantor Fitzgerald Healthcare Conference 2018 and the 2018 BIO Investor Forum
-
Cantor Fitzgerald Downgrades MedEquities Realty Trust (MRT) to Neutral

